Small molecule inhibitors of autophagy and histone deactylases and uses thereof
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsJennifer S. Carew, Steffan Nawrocki, Wei Wang
Life of this patent
Estimating the term…
Abstract
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).
Claims12
A compound encompassed within one of the following formulas:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof,
- wherein U is selected from carbon and nitrogen;
- wherein V is selected from carbon and nitrogen;
- wherein W is selected from carbon and nitrogen;
- wherein X is selected from
- wherein Y is selected from S, NH, NCH3, and oxygen;
- wherein Z is selected from carbon and nitrogen;
- wherein R1 is selected from hydroxyl,
- wherein R2 is selected from hydrogen, methyl,
- wherein each of R3, R4, R5, and R6 is independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxyl, and NH2;
- wherein R7 is selected from hydrogen, methyl, and deuterated methyl;
- wherein R8 is selected from hydrogen,
- wherein R9 is selected from hydrogen, methyl,
A compound selected from the group of
Dependencies are inferred from the claim text.